The Sanguine Difference
By simplifying the patient donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.
Our Success In Numbers
1000+
Studies
Completed
15,000+
Home Visits Completed
25+
Top Pharma
Clients
100+
Nonprofit Organization Partnerships
70,000+
Patient Member Community
How the Legacy Indirect Model Stacks Up Against Ours
- Patient Access
Patient Centricity- Strategies for reach, recruitment, retention
- Diversity of participant pool including hard-to-reach populations
- Study participant recontact ability
- Patient Community Access
- Panoramic, long-term view of study participants
- Clinically Relevant Specimen + Data
- Biospecimen procurement
- Sample integrity
- Biospecimen and data owner
- Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
- Longitudinal sampling
- Simultaneous collection of multiple biospecimen types
- Large volume blood specimen collection (≤180 mL)
- Patient-reported outcomes data
- Same-day sample collection and delivery
- Renewable medical record-derived data
Us
Direct Patient Access
- Patient Access
-
Patient Centricity
Engaged homegrown communities
-
Strategies for reach, recruitment, retention
Mobile, virtual, flexible
-
Diversity of participant pool including hard-to-reach populations
Unlimited by geographic reach and access to medical facility
-
Study participant recontact ability
In-home
-
Patient Community Access
Broad, multi-faceted
-
Panoramic, long-term view of study participants
High retention, amendable study design, 95% patient retention rate
- Clinically Relevant Specimen + Data
-
Biospecimen procurement
Yes
-
Sample integrity
Yes
-
Biospecimen and data owner
Yes
-
Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
Yes -
Longitudinal sampling
Yes -
Simultaneous collection of multiple biospecimen types
Yes
-
Large volume blood specimen collection (≤180 mL)
Yes
-
Patient-reported outcomes data
Yes
-
Same-day sample collection and delivery
Yes
-
Renewable medical record-derived data
Yes
Biobanks
Indirect Patient Access
- Patient Access
-
Patient Centricity
Third-party mediated, transactional
-
Strategies for reach, recruitment, retention
Confined, brick and mortar
-
Diversity of participant pool including hard-to-reach populations
Limited by geographic reach and access to medical facility
-
Study participant recontact ability
Clinical collection center
-
Patient Community Access
Oncology specialized
-
Panoramic, long-term view of study participants
Low to no patient retention
- Clinically Relevant Specimen + Data
-
Biospecimen procurement
No
-
Sample integrity
No
-
Biospecimen and data owner
No
-
Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
No
-
Longitudinal sampling
No -
Simultaneous collection of multiple biospecimen types
No
-
Large volume blood specimen collection (≤180 mL)
No
-
Patient-reported outcomes data
No
-
Same-day sample collection and delivery
No
-
Renewable medical record-derived data
No
Thank you for considering Sanguine to be your partner in study design, recruitment, biospecimen, and data collection. We have worked with leading pharmaceutical and biotech companies for over 10 years to expedite the completion of more than 1000 research studies to date.
To provide you with an accurate quote, please complete the short form here.
Alternatively, to speak with someone directly, please contact:
Phone: 818-462-8290
Email:
Contact Information
Access challenging, hard-to-collect samples
Sanguine's unique patient-centric approach to biospecimen collection gives researchers access to rare patient populations and complex study designs such as event-based collection, longitudinal collections, and more.
Are you a researcher?
Find out how Sanguine can accelerate your study.